US · Healthcare · Medical Devices
EPS came in at 0.80 against a street estimate of 0.73 — a beat of 9.6%.
Analysts rate Edwards Lifesciences Corp a buy (23 buy, 7 hold, 0 sell out of 30) with an average price target of $102.53.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.20% |
| Vanguard Capital Management, LLC | 6.53% |
| Vanguard Portfolio Management, LLC | 4.58% |
| State Street Corp | 4.57% |
| JPMorgan Chase & Co | 3.95% |
| Wellington Management Company LLP | 2.92% |
| Geode Capital Management, LLC | 2.68% |
| Bank of New York Mellon Corp | 2.44% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales were $1,715.5 million, up from $1,553.1 million in the third quarter of 2025. • Nine-month 2026 net | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 sales increased 10.5% to $1.72 billion; constant-currency growth was 11.2%. • GAAP diluted EPS was $0.53, compared with $0.50 | 2026-11-04 |
| Board / officer change · Q3 2026 EDWARDS LIFESCIENCES CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial results or numerical performance data disclosed in this filing • | 2026-08-28 |
| Quarterly report · Q2 2026 EDWARDS LIFESCIENCES CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $1,741.0 million (vs. $1,532.2 million in Q2 2025) – u | 2026-08-04 |
| Results announced · Q3 2026 EDWARDS LIFESCIENCES CORPORATION – Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total sales: $1.74 billion, up 13.6% year-over-year (12.5% con | 2026-07-23 |
| Board / officer change · Q2 2026 EDWARDS LIFESCIENCES CORPORATION – FORM 8-K SUMMARY Report Date: May 7, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Edwards Lifesciences Corporation i | 2026-05-08 |
| Quarterly report · Q1 2026 EDWARDS LIFESCIENCES CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales Q1 2026: $1,648.6 million vs. $1,412.7 million Q1 2025 (+16.7% | 2026-05-06 |
| Board / officer change · Q2 2026 EDWARDS LIFESCIENCES CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • New Chief Financial Officer appointment effective May 29, 2026 • Sign-on bonu | 2026-05-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Edwards Lifesciences Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.